UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
This quick guide explains typical candidates for credit builder loans and the situations where they can be most effective in building credit.
24,219 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Markets swing wildly during downturns, testing nerves and portfolios. Here are three stock market turmoil: crucial st...
A mid-February 2026 SEC filing shows Bank Hapoalim taking a new position in the FTCS ETF, worth about $14.7 million. ...
The EV market is shifting quickly, and two growth stocks sit at opposite ends of the spectrum: Tesla and Rivian. This...
Gas-price swings touch every part of the economy and your portfolio. This guide breaks down what's driving those move...
Two popular U.S. dividend ETFs take different paths to income. This guide breaks down how SCHD and FDVV approach divi...
Since 2020, five magnificent stocks have split their shares. Only Alphabet and Tesla outpaced the market, proving tha...
A high-stakes legal clash between Archer Aviation and Joby could swing how investors price the whole eVTOL space. Her...
Dreaming of a portfolio that compounds for decades? This article lays out three growth stocks hold forever that pass ...
A landmark joint interpretive guidance from the SEC and CFTC clarifies crypto regulation, focusing on security classi...
NVIDIA riding robust AI demand, elevated data-center spending, and resilient margins as 2026 unfolds. Analysts weigh ...
Shay Capital reduced its PureCycle stake in the latest 13F filing, prompting questions about the stock's future. This...